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Abstract 
                                                                                                                                                             
Background: In 2002, a poster alerted the French health authorities to the possibility that the 
risk of childhood leukaemia might be increased by hepatitis B vaccination. Elucidating the 
role of vaccination in the etiology of childhood acute leukaemia was therefore included in the 
objectives of an ongoing national study.  
Methods: The ESCALE study was a French national population-based case-control study 
conducted in France in 2003 and 2004 in order to investigate the role of infectious, 
environmental and genetic factors in 4 childhood neoplastic diseases (leukaemia, lymphoma, 
neuroblastoma, and brain tumor). The controls were randomly selected from the French 
population and age and gender frequency matched with the cases. A total of 776 cases of 
acute leukaemia (91% of the eligible cases) and 1681 controls (69% of the eligible controls) 
were included. In a specific standardized telephone interview, which was the same for both 
the cases and controls, each mother was asked to read out her child's complete vaccination 
record.  
Results: No association between vaccination and the risk of childhood acute leukaemia (ALL 
or AML) was observed. No relationship between the risk of leukaemia and the type of 
vaccine, number of doses of each vaccine, total number of injections, total number of vaccine 
doses or number of early vaccinations was evidenced. No confounding factor was observed.  
Conclusion: The study did not show any evidence of a role of vaccination in the etiology of 
childhood leukaemia. 
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Introduction 
In 2002, a poster alerted the French health authorities to the possibility that the risk of 
childhood leukaemia might be increased by hepatitis B vaccination1. The potential public 
health implications of such an association provided the rationale for detailed investigation in 
the context of the Escale national population-based case-control study of the etiology of 
childhood cancer. Childhood leukaemia is the most common childhood cancer worldwide. In 
France, the incidence is 43 cases per million people and per year, equivalent to about 470 
new cases diagnosed each year1. Very few risk factors, such as high dose ionizing radiation, 
some chemotherapeutic regimens and some genetic syndromes (Down syndrome, Fanconi 
syndrome), have been identified. Current research is focusing on infectious, environmental 
and genetic factors which may influence the risk of childhood leukaemia. Since leukaemia is 
a neoplastic disease of immune cells, a relationship between immune system events, such 
as infection, atopic disease or vaccination, and the risk of childhood leukaemia has been 
suggested. This paper investigates the relationship between vaccination and the risk of the 
immunologic subtypes of childhood acute leukaemia (AL): acute lymphoblastic leukaemia 
(ALL) and acute myeloblastic leukaemia (AML).  
 
 
                                                 
1 Ma X, Does M, Buffler PA, Wiencke JK. Hepatitis B vaccination and the risk of childhood leukaemia. Poster 
session abstract 3801, American Association for Cancer Research annual meeting, San Francisco, April, 2002 
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Methods 
 
The ESCALE study, a national, comprehensive, case-control study conducted in 2003 and 
2004, addressed 4 childhood neoplastic diseases (leukaemia, lymphoma, neuroblastoma 
and brain tumor) and infectious, environmental and genetic potential risk factors. 
 Study population 
Each case of acute leukaemia incident in 2003-2004 in a child aged less than 15 years, 
residing in France at the time of diagnosis and with no previous history of malignancy was 
eligible. All the childhood leukaemia cases were confirmed by bone marrow analysis. 
Children whose mother did not speak French or who had been adopted were not eligible. 
The cases’ mothers were interviewed at least 2 months after diagnosis, within 5 months on 
average. For ethical reasons, the mothers of children who died before the scheduled 
interview date were not interviewed. The leukaemia cases were recruited directly by 
investigators assigned to each French pediatric oncology hospital department, with the 
support of the French National Registry of Childhood Hematopoietic Malignancies. Out of the 
948 cases of childhood acute leukaemia diagnosed in France from January 1, 2003, to 
December 31, 2004, 860 cases were eligible. The reasons for exclusion consisted in: 
absence of a biological mother (10 cases); non-French-speaking mother (29 cases); serious 
psychological disorders (14 cases); physician’s refusal (1 case); and death (34 cases). 
Finally,  776 (91%) case mothers have given their consent and been interviewed. 
The controls were randomly selected from the French population using quotas, a priori 
determined to make the control group representative of all cancer cases in terms of age and 
gender. Additional quotas constrained the control group to have the same distribution as the 
national population in terms of number of children living in the household, conditionally to the 
age group. Random selection was based on a representative sample of 60,000 addresses 
from the French national telephone directory plus unlisted numbers, which have been 
randomly retrieved before dialling. Among the 50,217 phone numbers dialled, 27,633 
belonged to a household and 8,500 (30.8%) to a target household. Of them, 862 hanged up 
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before eligibility could have been checked and 5,277 suited to an already completed quota. 
Finally, among the 2361 eligible control mothers, 679 refused the interview and 1682 (71.2%) 
gave their consent and were interviewed. We then excluded one control who had a prior 
history of neuroblastoma, to end with a total number of 1681 controls. 
  
Data collection 
Each of the case and control biological mothers responded to a personal and standardized 
telephone interview lasting 40 minutes. The interview elicited data on demographic and 
socio-economic characteristics, parental occupational history, childhood environment, familial 
and personal medical history, and history of the pregnancy.  
In France, the vaccination section of a child’s medical record contains a separate page for 
each vaccine. The healthcare professional reports the proprietary name of the vaccine and 
the date of vaccination on the appropriate page. For the study, each mother was asked to 
read out each page of the vaccination record, line by line. Each interviewer’s computer 
screen displayed a vaccination record template and an exhaustive list, by record page, of the 
proprietary names of the vaccines available. Each vaccine administered and the vaccination 
date were thus obtained. The mother’s history of hepatitis B (disease and vaccination) was 
reported in the same way. 
 
Since combined vaccines are frequently administered, four vaccination parameters were 
considered: vaccine type; the number of doses of each vaccine (vaccine doses); the total 
number of injections; and the total number of vaccine doses received (all vaccines taken 
together). These variables were all treated as categorical variables. For example, 2 DTP 
(diphtheria + tetanus + poliomyelitis) vaccinations and 1 BCG vaccination are equivalent to 4 
vaccines; 2 diphtheria vaccine doses + 2 polio vaccine doses + 2 tetanus vaccine doses + 1 
BCG vaccine dose; 3 injections; and a total of 7 vaccine doses. In France, during the 6 first 
months of life, children usually receive 4 vaccines: BCG, diphtheria, tetanus and poliomyelitis 
(DTP: usually in one injection). If parents wish, additional recommended vaccines such as 
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Haemophilus influenzae B (Hib) and pertussis vaccines (both combined with the DTP 
injection) and Hepatitis B vaccine may also be administered. In some contexts, such as 
chronic disease, the child's physician may also recommend pneumococcal and 
meningococcal immunization. Pneumococcal immunization has recently been recommended 
for infants aged less than 2 years attending daycare. During the first 6 months of life, a child 
may thus receive up to 9 different vaccines, 12 injections and 24 vaccine doses (Figure 1). 
Vaccination is usually not scheduled for infants aged 6 months to 1 year. Even though the 
French immunization calendar recommends early vaccination, only four vaccines are 
mandatory (BCG, diphtheria, tetanus and poliomyelitis) and required for starting school at 
age 6 years. 
 
Statistical analysis 
The SAS® software package (version 8, Cary, North Carolina) was used for all the analyses. 
Non-conditional logistic regression was used to estimate odds ratios (OR) and 95% 
confidence intervals (CI), with adjustment for age and gender. In order to compare the 
different types of leukaemia, analyses were carried out using polytomous logistic regression. 
Age adjustment for children aged less than 2 years was conducted at intervals of 3 months. 
For the other age groups, adjustment complied with the stratification categories. 
When the exact day of injection was not reported, a default value of 15 was allocated. When 
the month was not reported, the date was considered missing. Only 25 case mothers (3.2%), 
consisting in 18 ALL (2.9%), 5 AML (5.5%) and 2 other types of AL, and 34 control mothers 
(2.1%) did not manage to have their child's immunization records for the interview. 
Pre-diagnosis symptoms of childhood leukaemia such as fever, extreme fatigue or bone pain 
develop, at the latest, 2 or 3 months before diagnosis. As such symptoms may result in the 
child's physician postponing a scheduled vaccination, the vaccination data were censored at 
6 months before the reference date for cases and controls. Similarly, surgery or disease 
related to a malformation (38 cases and 56 controls) or genetic abnormality (14 cases and 5 
controls) may result in a scheduled vaccination date being modified. In consequence, those 
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cases and controls were excluded from analysis. Thus, out of the 776 cases and 1681 
controls who were eligible, 726 cases (3 cases presented with both a malformation and a 
genetic abnormality) and 1620 controls were included in the analysis. When analyses 
concerned a given step of the vaccination calendar, only children having reached at least the 
corresponding age plus 6 months were included, so that both cases and controls could have 
completed this step. Therefore, analyses made for vaccinations before 6 months and 18 
months were carried out among children at least 1 year and 2 years old, respectively. 
 
Results 
Among the 726 cases, 620 (85%) presented with acute lymphoblastic leukaemia, 91 (13%) 
with myeloblastic leukaemia, 11 (2%) with biphenotypic leukaemia and 4 with acute 
leukaemia with no immunophenotyping at the date of interview. 
 
The cases and controls did not differ with respect to gender or the number of children living 
in the household (table 1). There was a small age discrepancy between the cases and 
controls, particularly for very young children, who were more strongly represented in the 
control group. The discrepancy simply reflects the fact that the cases were only a fraction of 
the total case population of the ESCALE study, since only the leukaemia cases are 
considered herein. There was at least one control for each case in each age group. Cases 
and controls were similar with respect to age (mean age 6,0 years for controls and 5,6 years 
for cases), maternal education or degree of urbanization. The paternal educational level was, 
however, higher for the controls. 
 
About 40% of the mothers reported hepatitis B immunization before pregnancy (301 case 
and 719 control mothers) while only 25 mothers (6 case and 19 control mothers) reported 
having had hepatitis B.  
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At age 6 months, most of the children had been immunized against tuberculosis, diphtheria, 
tetanus, polio, pertussis and Hib (Table 2). About one third of the children had been 
immunized against hepatitis B and less than 10% against Meningococcus or Pneumococcus. 
At age 18 months, most of the children had also been immunized against measles, mumps 
and rubella (Table 3).  
 
The distribution of hepatitis B immunization was similar for the cases and controls (35.9% vs 
35.6%: OR=1,0 [0.8-1.3]), for ALL (34.8% vs 35.6%: OR=1,0 [0.8-1.2]) and for AML (40.8% 
vs 35.6%: OR=1,3 [0.8-2.1]). The results were unchanged after adjustment for the mothers’ 
hepatitis B status (disease and immunization). 
 
No association between the number of injections received and the risk of childhood 
leukaemia was observed (table 4). The results were the same for ALL alone and for AML 
alone. There was no association between the total number of vaccine doses received and 
the risk of acute leukaemia, ALL or AML. 
 
A child aged 6 months should have received at least 4 injections (1 BCG and 3 DTP). An 
investigation to determine whether an unvaccinated or less-vaccinated status was associated 
with a risk of childhood leukaemia was therefore conducted. For all types of acute leukaemia 
taken together, there was no association between the number of injections or doses received 
before age 6 months and the risk of childhood leukaemia (table 5). The results were the 
same for ALL. An unvaccinated or less-vaccinated (1 or 2 injections) status was positively 
associated with a risk of acute myeloblastic leukaemia. Most of the less-vaccinated children 
(17/21) had not received BCG vaccine. However, this association observed with injections 
before 6 months was unstable for AML: the proportion of children with AML unvaccinated or 
less vaccinated no more differed to that of the controls when we set the threshold for early 
injections to 4 (31% of children with 3 or more injections in cases and 33% in controls before 
4 months) or 8 months (82% of children with 3 or more injections in cases and 86% in 
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controls before 8 months) instead of 6 months (58% of children with 3 or more injections in 
cases and 74% in controls before 6 months).  
 
Adjustment for birth order, maternal and paternal educational level and degree of 
urbanization, which were related to variables such as the number of injections received and 
age of vaccination, did not modify any of the results for AL, ALL or AML. 
 
Discussion 
 
 
ESCALE was the first national study to include all the cases of frequent childhood neoplastic 
diseases (leukaemia, lymphoma, neuroblastoma and brain tumor) diagnosed in France over 
a two-year period (2003 - 2004). With a 5 % alpha error, the statistical power of the study 
was greater than 80% for most results. 
The study showed no evidence of a relationship between vaccination and the risk of 
childhood acute leukaemia (ALL or AML), irrespective of the vaccine (including hepatitis B 
vaccine), total number of injections received or total number of vaccine doses received.  
There was no evidence for a relationship between unvaccinated or less-vaccinated status at 
age 6 months and the risk of acute leukaemia or ALL.  
 
The French National Registry of Childhood Hematopoietic Malignancies includes all the 
cases of childhood leukaemia diagnosed in the population of mainland France aged less 
than 15 years since January 1990. The exhaustiveness of the registry has been estimated to 
be 99.2% for leukaemia1. It is therefore probable that almost all the cases diagnosed in 2003 
and 2004 were registered. Since there is no evidence for a relationship between vaccination 
history and the prognosis of leukaemia, the exclusion of early deaths for ethical reasons is 
unlikely to have induced a selection bias. 
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The controls were randomly selected from the overall population. The national telephone 
directory was used as the basis for random selection, given that the subpopulation of 
telephone owners is comparable to the overall population as regards most sociodemographic 
characteristics and lifestyle. Unlisted numbers were computer generated prior to the random 
selection in order to avoid selection bias. The cases and controls did not differ with respect to 
age (considering all types of cancer) or gender. There was no difference between the 
controls and overall population with regard to birth order 2-4, indicating that the quota 
recruitment process was successful. The controls were representative of the national 
population in terms of the number of children (0-14) living in the household, which was used 
as a proxy of birth order, in order to prevent selection bias. Birth order may be, indeed, highly 
sensitive to the sampling process and may also be related to a number of other variables 
such as early daycare, early common infections5 and compliance with the recommended 
vaccination program6. The control mothers’ educational level was very similar to that of the 
French population 2-4 but the control fathers’ educational level was higher than that of the 
overall population. However, the results were unchanged after adjusting for those two 
variables. A report on childhood vaccinal coverage 7 showed that, in France (1998), 97% of 
2-year-old children had been immunized against diphtheria, poliomyelitis and tetanus, 81% 
against tuberculosis, 82% against measles and rubella, and 96% against mumps compared 
to 95%, 90%, 88% and 88%, respectively, in the 2-year-old controls in 2003 and 2004.. The 
immunization status of the controls was thus very similar to that of the overall population. 
The vaccination data were as objective as possible since each mother was asked to read out 
her child's vaccination records line by line. Moreover, in order to prevent recall bias, 
responses given by mothers unable to consult the vaccination records were considered 
missing data. Some vaccination records may have been incompletely filled out by the 
children’s physicians. However, this should not have induced differential bias since record 
completion was independent of case/control status. A recent study has shown that children’s 
personal health record are usually complete 8. It is therefore likely that vaccination records 
are also complete. It was difficult to exclude interviewer error in data recording. In order to 
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minimize the risk of error, particularly that associated with the emotional stress of 
interviewing cases’ mothers, the same standardized questionnaire was used for both the 
cases and controls and each interviewer interviewed both case and control mothers. 
The data on vaccinations 6 months prior to the reference date were censored. However, the 
results remained unchanged when none of those data were censored. 
Most of the cases and controls had been immunized against tuberculosis, diphtheria, 
tetanus, poliomyelitis, pertussis and Hib at the reference date and very few children had 
never been vaccinated. There were no differences between the cases and controls. The 
results with regard to immunization prevalence rates and the lack of association with the risk 
of childhood leukaemia are consistent with those of most studies 9-13. 
An association between hepatitis B vaccination and the risk of childhood leukaemia has been 
suggested in a preliminary report from the Northern California Childhood Leukaemia Study 
14. The present study provided no evidence of such an association irrespective of the type of 
acute leukaemia, age or number of vaccine doses received. These results are consistent 
with the final results of the Northern California Childhood Leukaemia Study11 and with the 
two studies that have investigated hepatitis B vaccination and the risk of acute leukaemia 9, 
11. This study is the first to include the mother's hepatitis B status in the analysis. Maternal 
hepatitis B status could not, therefore, have constituted a confounding factor. 
Several studies have reported an increasing negative association between the number of 
vaccine or combined-vaccine injections received and the risk of childhood acute leukaemia9, 
11-13. Only one study of the relationship between the overall number of injections and the risk 
of ALL has been published 13. It showed the same increasing negative association. None of 
those studies addressed the relationship between the number of doses received and the risk 
of acute leukaemia other than ALL. In this study, there was no obvious association between 
the number of injections received or the number of vaccine doses received and the risk of 
ALL or AML.  
Given that a relationship between a low number of early common infections and the risk of 
acute leukaemia has been suggested in several articles 5, 15-19, it was considered pertinent to 
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address the relationship between delayed early vaccinations and the risk of childhood 
leukaemia. No relationship between delayed early vaccinations and the risk of ALL was 
detected. An association was found for AML with fewer injections before the age of 6 
months, but it appeared unstable and without any trend as regards the age of injections, 
suggesting that this association was most probably observed by chance. 
 
Despite the statistical power of the study (80%), no evidence of a relationship between 
vaccination and the risk of acute lymphoblastic or myeloblastic leukaemia was evidenced 
irrespective of the type of vaccine, number of doses or number of early vaccinations. 
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Figure 1: French infantile vaccination calendar (1st year of life) 
 
 
 
 
BCG     X            
Diphtheria   X X X         
Tetanus   X X X         
Poliomyelitis   X X X         
Pertussis   X X X         
Hib   X X X         
Hepatitis B   X X         X 
Measles             X 
Mumps             X 
Rubella             X 
Pneumococcus   X X X         
Meningococcus   X X X         
 
 
 
 
Birth 6
 Age (months) 
121 2 3 4 5 7 8 9 10 11 
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Table 1: Characteristics of the cases and controls 
 Cases 
(n = 726) 
Controls 
(n = 1620) 
Control/Case 
ratio 
 
p 
 n % n %   
Gender      ns 
 Male  395  54.4 892 55.1 2.3  
Age at the reference date (years)   <0.01 
  < 2   108  14.9 362 22.4 3.4  
  2   98  13.5 146 9.0 1.5  
  3-4   185  25.5 293 18.1 1.6  
  5-6   114  15.7 218 13.5 1.9  
  7-8   74  10.2 160 9.9 2.2  
  9-11   88  12.1 217 13.4 2.5  
  12-14   59  8.1 224 13.8 3.8  
Number of children (0-14 years) living in the household  ns 
  1  226  31.1 528 32.6 2.3  
  2  321  44.2 688 42.5 2.1  
  ≥ 3  175  24.1 404 24.9 2.3  
  Missing data  4  0.6 0 0.0   
Birth order     <0.01 
  1  362  49.9 685 42.3 1.9  
  2  232  32.0 589 36.4 2.5  
  ≥ 3  132  18.2 346 21.4 2.6  
Daycare   ns 
  No  634  87.3 1418 87.5 2.2  
  Yes  92  12.7 202 12.5 2.2  
Maternal educational level  ns 
  ≤ High school  438  60.3 939 58.0 2.1  
  > High school  288  39.7 681 42.0 2.4  
Paternal educational level    0.02 
  ≤ High school  497  68.5 1021 63.0 2.1  
  > High school  222  30.6 584 36.1 2.6  
  Missing data  7  1.0 15 0.9   
Degree of urbanization  ns 
  Rural  226  31.1 569 35.1 2.5  
  Mixed  171  23.6 367 22.7 2.1  
  Urban  315  43.4 658 40.6 2.1  
  Missing data  14  1.9 26 1.6   
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Table 2: Vaccines usually administered before age 6 months (children's age > 1 year) 
 Controls (n = 1434) 
AL 
(n = 696) 
ALL 
(n = 606) 
AML 
(n = 76) 
 n (%) n (%) n (%) n (%) 
BCG   
   Yes  1309 (91.3) 624 (89.7) 548 (90.4) 63 (82.9) 
   No  94 (6.6) 48 (6.9) 39 (6.4) 8 (10.5) 
   Missing data  31 (2.2) 24 (3.5) 19 (3.1) 5 (6.6) 
Diphtheria        
   Yes  1365 (95.2) 663 (95.3) 578 (95.4) 71 (93.4) 
   No  38 (2.7) 9 (1.3) 9 (1.5) 0 (0.0) 
   Missing data  31 (2.2) 24 (3.5) 19 (3.1) 5 (6.6) 
Tetanus        
   Yes  1368 (95.4) 664 (95.4) 579 (95.5) 71 (93.4) 
   No  35 (2.4) 8 (1.2) 8 (1.3) 0 (0.0) 
   Missing data  31 (2.2) 24 (3.5) 19 (3.1) 5 (6.6) 
Poliomyelitis        
   Yes  1366 (95.3) 665 (95.6) 580 (95.7) 71 (93.4) 
   No  37 (2.6) 7 (1.0) 7 (1.2) 0 (0.0) 
   Missing data  31 (2.2) 24 (3.5) 19 (3.1) 5 (6.6) 
Pertussis        
   Yes  1325 (92.4) 646 (92.8) 565 (93.2) 67 (88.2) 
   No  78 (5.4) 26 (3.7) 22 (3.6) 4 (5.3) 
   Missing data  31 (2.2) 24 (3.5) 19 (3.1) 5 (6.6) 
Hepatitis B        
   Yes  510 (35.6) 250 (35.9) 211 (34.8) 31 (40.8) 
   No  893 (62.3) 422 (60.6) 376 (62.1) 40 (52.6) 
   Missing data  31 (2.2) 24 (3.5) 19 (3.1) 5 (6.6) 
Hib        
   Yes  1132 (78.9) 582 (83.6) 512 (84.5) 58 (76.3) 
   No  271 (18.9) 90 (12.9) 75 (12.4) 13 (17.1) 
   Unknown  31 (2.2) 24 (3.5) 19 (3.1) 5 (6.6) 
Pneumococcus        
   Yes  101 (7.0) 30 (4.3) 24 (4.0) 5 (6.6) 
   No  1302 (90.8) 642 (92.2) 563 (92.9) 66 (86.8) 
   Missing data  31 (2.2) 24 (3.5) 19 (3.1) 5 (6.6) 
Meningococcus        
   Yes  71 (5.0) 31 (4.5) 28 (4.6) 2 (2.6) 
   No  1332 (92.9) 641 (92.1) 559 (92.2) 69 (90.8) 
   Missing data  31 (2.2) 24 (3.5) 19 (3.1) 5 (6.6) 
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Table 3: Vaccines usually administered before age 18 months (children's age > 2 years) 
 Controls 
(n = 1258) 
AL 
(n = 618) 
ALL 
(n = 544) 
AML 
(n = 62) 
 n (%) n (%) n (%) n (%) 
Measles   
  Yes 1110 (88.2) 541 (87.5) 480 (88.2) 50 (80.7) 
   No 119 (9.5) 55 (8.9) 46 (8.5) 8 (12.9) 
   Missing data 29 (2.3) 22 (3.6) 18 (3.3) 4 (6.5) 
Mumps         
  Yes 1103 (87.7) 539 (87.2) 478 (87.9) 50 (80.7) 
   No 126 (10.0) 57 (9.2) 48 (8.8) 8 (12.9) 
   Missing data 29 (2.3) 22 (3.6) 18 (3.3) 4 (6.5) 
Rubella         
  Yes 1104 (87.8) 540 (87.4) 479 (88.1) 50 (80.7) 
   No 125 (9.9) 56 (9.1) 47 (8.6) 8 (12.9) 
   Missing data 29 (2.3) 22 (3.6) 18 (3.3) 4 (6.5) 
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Appendix (SFCE Investigators of the ESCALE study) 
 
Principal Investigator Hospital City (France) 
André Baruchel Hôpital Saint-Louis 
Hôpital Robert Debré  
Paris 
Catherine Behar American Memorial Hospital Reims 
Claire Berger Centre Hospitalier Universitaire Saint-Etienne 
Christophe Bergeron Centre Léon Bérard Lyon 
Jean-Louis Bernard Hôpital La Timone Marseille 
Pierre Bordigoni Centre Hospitalier Universitaire Nancy 
Patrick Boutard Centre Hospitalier Régional 
Universitaire 
Caen 
Gérard Couillault Hôpital d’Enfants Dijon 
Lionel De Lumley Centre Hospitalier Régional 
Universitaire 
Limoges 
Anne-Sophie Defachelles Centre Oscar Lambrais Lille 
François Demeocq Hôpital Hôtel-Dieu Clermont-
Ferrand 
Alain Fisher Hôpital des Enfants Malades Paris 
Virginie Gandemer Hôpital Sud Rennes 
Olivier Hartmann Institut Gustave Roussy Villejuif 
Jean-Pierre Lamagnere Centre Gatien de Clocheville Tours 
Françoise Lapierre Centre Hospitalier Universitaire 
Jean Bernard 
Poitiers 
Guy Leverger Hôpital Armand Trousseau Paris 
Patrick Lutz Hôpital de Hautepierre Strasbourg 
Geneviève Marguerite Arnaud de Villeneuve Montpellier 
Françoise Mechinaud Hôpital Mère et Enfants Nantes 
Gérard Michel Hôpital La Timone  Marseille 
Jean Michon Institut Curie Paris 
Frédéric Millot Centre Hospitalier Universitaire 
Jean Bernard 
Poitiers 
Brigitte Nelken Hôpital Jeanne de Flandre Lille 
Brigitte Pautard Centre Hospitalier Universitaire Amiens 
Yves Perel Hôpital Pellegrin - le Tripode Bordeaux 
Yves Bertrand Hôpital Debrousse Lyon 
Alain Pierre-Kahn Hôpital des Enfants Malades Paris 
Emmanuel Plouvier Centre Hospitalier Régional Besançon 
Xavier Rialland Centre Hospitalier Universitaire Angers 
Alain Robert Hôpital des Enfants Toulouse 
Hervé Rubie Hôpital des Enfants Toulouse 
Nicolas Sirvent Hôpital L’Archet Nice 
Christine Soler Fondation Lenval Nice 
Danièle Sommelet Centre Hospitalier Universitaire Nancy 
Jean-Pierre Vannier Hôpital Charles Nicolle Rouen 
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